Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
News should be out any day. Most bios with good Phase2A results have market caps of at least 50M, so at 14M Kalytera is crazily undervalued.
Although this company appears promising and seems to be making tons of good moves, after doing some DD some things seem kinda weird and suspect. I am not trying to bash and feel free to correct me or give insight.
CEO Michael Yorke: It's hard to find much info on the guy besides he is the CEO of Crop and is still in college? Kinda bizarre to be a CEO and still working on your degree. He also has been a capoeira instructor for 15 years? He appears really young and there is nothing about Crop on his personal FB. Kinda strange.
https://www.facebook.com/michael.yorke/photos?lst=504161722%3A507923942%3A1557873185
Their CFO Abbey Abdiye is a CFO of a failing penny stock Tower Wireless.
Here's where it gets real weird their Vice President, Andrea Castiglione, is 27 years old and is a Crypto trader. On his FB and twitter there is zero mention of Crop whatsoever. It's all about his crypto business (very suspect).
https://www.facebook.com/castiglioneand
https://twitter.com/castiglioneand?lang=en
Doing some DD on their Nevada 1012 Acre purchase is pretty strange too. Their subsidiary Elite Ventures group is pretty shady looking. Here is their address (AKA a PO box in a UPS store)
https://www.google.com/maps/uv?hl=en&pb=!1s0x80c2b37f96055555:0x13fc8ef31002f8c8!2m22!2m2!1i80!2i80!3m1!2i20!16m16!1b1!2m2!1m1!1e1!2m2!1m1!1e3!2m2!1m1!1e5!2m2!1m1!1e4!2m2!1m1!1e6!3m1!7e115!4s/maps/place/elite%2Bventures%2Bgroup/@33.8651053,-118.3948117,3a,75y,180.44h,90t/data%3D*213m4*211e1*213m2*211sJ_e83P193rdCPThHGXu7tw*212e0*214m2*213m1*211s0x80c2b37f96055555:0x13fc8ef31002f8c8?sa%3DX!5selite+ventures+group+-+Google+Search&imagekey=!1e2!2sJ_e83P193rdCPThHGXu7tw&sa=X&ved=2ahUKEwiVvuL4i5ziAhVLnp4KHQFUAdUQpx8wD3oECA4QBg
Also besides seeing tons of paid pumps and ads one of their directors works for StockHouse, the notorious pumping website.
Looking at some of their assets on their site raise some flags as well. Is their WA greenhouses up and running? I see numerous articles a year ago about updates, but yet on their site it is still pictures under construction. Hoop houses like that take like a week to build.
Again, a lot of things aren't adding up here. Feel free to correct me or give your thoughts.
https://cropcorp.com/
Speculation but:
s going on with your stock? The publishers latest predictions:
Don't Sweat It_ANTIBE THERAPEUTICS $ATBPF Involved In Secret Negotiations Involving Undisclosed Fortune 500 Company In Ontario, Canada
Yikes, chart is looking terrible. I had to do a 5 year chart to find the next support, looks to be .39US. And that's a small one, next is .31 than to low .20s.
Sucks, sorry guys. I used to be a big fan, after Gene it all went to shiat.
I agree. And their market cap is so low at this point, even at a 500% premium, they could be bought out for a measly 55M, which is nothing to a big pharma company.
Dilution is done! Fully funded for rest of Phase2 trials and news coming. This was a good post to remember:
Some figures to help out those who say this is worth nothing
If I remember right the report* said $400 exclusive market year one and adding $100 million per year to 2027 where it is estimated to be $1.3 billion. As we're not in year 1 since we have no drug - yet, I moved it to 2020 as year one with, the advance in market going up as per the rationale of the report. (All figures in USD not CD unless specified)
You can adjust the start time or years with completion but I'm just trying to show what kind of money we're talking about here.
2018 $
2019 $
2020 $ 600,000,000
2021 $ 700,000,000
2022 $ 800,000,000
2023 $ 900,000,000
2024 $1,000,000,000
2025 $1,100,000,000
2026 $1,200,000,000
2027 $1,300,000,000
Total $7,600,000,000 ($10,133,000,000 CD) over 8 years or $1.4 billion($1.86 CD) per year average. I'm no rocket scientist but with an exclusive market like that and present shares outstanding of 304 million at cap of $18 million, assuming fifty percent profit brings us to a profit of $12.5 per share ($16.6 CD) over that period.
Or, if it's 75% profit then share profit is $18.75 ($25 CD) Average over 8 years and it's $2.34 ($3.12 CD) per share.
In any case, if anybody is worried about dilution, as long as it's helping us get to the start line it's fine with me.
Of course, what do I know, I might be missing something here or, maybe missing everything. Any experts want to chime in?
*"The commercial opportunity for Kalytera’s CBD products for the prevention and treatment of GVHD is large. According to the January 2018 Market Forecast Report by DelveInsight Perspective, the potential market for a successful product for prevention and treatment of GVHD in the 7 major jurisdictions (the U.S., Germany, France, Italy, Spain, the U.K. and Japan) is estimated to be more than USD $408 million in 2018, and could grow to approximately USD $1.3 billion by 2027."
Read more at https://stockhouse.com/companies/bullboard?symbol=kaltf&postid=29590536#dfG0gd8Md272guYF.99
Big news coming in May! Now is the time to load up!
Epic video!
Next stop.....Teens! All Abooooooooard!
Something is brewing! Volume up like crazy.
Incredible write up on one of the most undervalued bios out there: Antibe Therapeutics
https://scr.zacks.com/News/Press-Releases/Press-Release-Details/2019/VATE-Set-to-Initiate-Phase-2b-Efficacy-Trial-for-ATB-346-Completes-CAD575-Million-Financing/default.aspx?fbclid=IwAR1KilurDyB5I8amwsuBL8CbbYIktQRkS463dC6U--SeZqd8hhM4-6FraWw
You guys ever hear of Antibe Therapeutics? One of my favorite undervalued bios. Never knew there was a slight Canopy connection.
Antibe
Business Development Advisory Board
¦ Rami Batal PhD, MBA
Former VP, Business Development for Purdue
Canada; brings to Antibe vast experience in the
pain markets
Currently VP, Medical Research of Canopy Growth,
a leading cannabis producer and innovator
Take with a grain of salt (stolen from Stock House)
"KALY rumor alert
I have just heard that GW Pharma is in ongoing discussions with Kalytera.
I’ve been told that GW Pharma will look for minority stake in KALY with options in exchange for ongoing guidance as well as capital to advance phase 3 trials.
Options would be exercised upon the successful completion of phase 3 which would give GW a majority stake and overall control.
I imagine this would garner a lot of interest in Kalytera."
Dr. Raphael Mechoulam, Ph.D., is the Co-Chair of the Scientific Advisory Board for Kalytera and also has a relationship with GW Pharma.
Take with a grain of salt (stolen from Stock House)
"KALY rumor alert
I have just heard that GW Pharma is in ongoing discussions with Kalytera.
I’ve been told that GW Pharma will look for minority stake in KALY with options in exchange for ongoing guidance as well as capital to advance phase 3 trials.
Options would be exercised upon the successful completion of phase 3 which would give GW a majority stake and overall control.
I imagine this would garner a lot of interest in Kalytera."
Dr. Raphael Mechoulam, Ph.D., is the Co-Chair of the Scientific Advisory Board for Kalytera and also has a relationship with GW Pharma.
Yeah I googled otcmarkets and sedar and it's blank. But they seem to have a bunch of products and have been around long enough to have earnings, so I find it odd. But thanks smart ass.
Checked both, there are none. Links? Thx
How come I cant find any of their financials? THanks
Short form Prospectus is available on sedar.
The Company intends to use the net proceeds of the Offering to increase the sample size of the upcoming Phase 2B dose-ranging, efficacy study for ATB-346. Based on the encouraging COX inhibition data from the human metabolism study completed in November 2018, the Company has increased the sample size of the upcoming study to 360 patients (from an originally planned 200 patients). This powers both the high dose (250 mg) and middle dose (200 mg) for statistical significance, and is expected to provide more robust efficacy data that can be leveraged for Phase 3 development and global partnering activity. This amendment to the study design is anticipated to cost an additional $1.15 million, bringing the total cost of the study to $4.35 million (net of prepayments).
The Company expects to fund $3.2 million of the total cost of the study with cash on hand plus expected warrant exercises and SR&ED credits, and anticipates funding the balance of $1.15 million with net proceeds from the Offering.
In addition, the Company intends to use the net proceeds of the Offering to fund certain activities for ATB-346 that will fulfill key requirements for the commencement of Phase 3 development and regulatory approval. These activities include: (i) long-range animal toxicology studies (6-month rat and 9-month canine studies); (ii) regulatory consulting fees for pre-IND and end-of-Phase-2 FDA meetings; and (iii) remaining pharmacokinetic metabolite studies.
Read more at https://stockhouse.com/companies/bullboard?symbol=v.ate&postid=29356805#W2WSRLsMZmLxLaCc.99
More great interim data:
Close as it gets to a slam dunk for bio world. Sneak peaks into Kalytera ongoing Phase 2 trial are going great! This horrible condition might finally have a preventative drug!
https://kalytera.co/news/kalytera-reports-additional-positive-data-for-cbd-in-prevention-of-acute-gvhd/?fbclid=IwAR2frfCAarT3MjtyI6berAWbvXdUn2TlCVi-arQPEJCxyAKKhwp6ddZbFnw
This Kaly is way better ha! See their latest interim results?
Probably early March I think. Should take a few weeks or month to finalize, publish etc
Great news in Israel, not directly related but could still be huge for Kalytera possibly.
https://www.jpost.com/Israel-News/Israel-gives-green-light-to-medical-cannabis-exports-578815
Some big news is coming, I can just feel it!
Aphria and Kalytera partnership or buyout?
This is just me speculating...but after speaking to the CEO of Kalytera, who said they are in talks with a Canadian LP to partner with, I am wondering if it could be Aphria?
Aphria has already bought millions worth of $KALTF in the past (not sure why they sold) and Aphrias chief science officer is still on the board of Kalytera. Considering the great interim results Kalytera just released, which suggest their 2b trial results should be great I am wondering if Aphria is eyeing them for a partnership or buyout.
I am long both.
Gary Leong, Director
Mr. Leong is the Chief Scientific Officer of Aphria Inc., a Health Canada licensed producer of medical cannabis products. Gary has a personal background in quality assurance, quality control, quality system audits, international and domestic regulatory affairs and product research and development. Gary currently is the president of Neautrical Solutions Inc. located in Surrey, British Columbia. Prior to that, he was the Chief Scientific Officer at Jamieson Laboratories Limited. He began at Jamieson in the year 2000 as the Vice President of Scientific and Technical Affairs. He also held the position of Quality Control Manager at Boehringer Ingelheim Consumer Products: Quest Vitamins and Development Officer at Atomic Energy of Canada: Radiochemical Company. Gary’s educational background began with a Bachelors of Science in Chemistry and has taken him most recently to an MBA in Quality Management from City University of Bellevue Washington. Gary is currently affiliated with The Life Sciences Working Team of Windsor-Essex Economic Development Corporation. In the past, he was a member of the Natural Health Products Directorate Program Advisory Committee and a board member of the Ontario Ginseng Innovation and Research Consortium.
What a day! Yessssss
Based on what the CEO told me the interim results were the lowest dosage of CBD treatment. We all know CBD is extremely safe, so the full results are almost a slam dunk. The higher dosage should be even more effective.
Aphria bought millions worth at .40US (yes they sold, but the Aphria Chief Science Officer is still on Kalytera board of directors)
I could easily see this going back to the .40s range soon and way higher if Phase2B are great, which I expect them to be.
Way bigger volume on Canadian side. Dilution drying up and people buying up these deals.
Looks like it just needs to blow through $9.38 and blue skies ahead.
Just getting warmed up. Tax loss selling done, this was easy to drop and it will be easy to move back up.
Practically free at this point! Insanely great loading zone.
Very undervalued at these 52 week lows, dilution drying up and big news on horizon. These cheapies are a gift, can't wait to see this back in the .40s and up soon.
Pretty happy about my purchase so far (: If it dips again later i'll buy more. Anything under $30 is a steal, just based on Constellation deal alone.